CA2663027A1

CA2663027A1 - Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181

Info

Publication number: CA2663027A1
Application number: CA002663027A
Authority: CA
Inventors: Carlo M. Croce
Original assignee: The Ohio State University Research Foundation; Carlo M. Croce
Current assignee: Ohio State University Research Foundation
Priority date: 2006-09-19
Filing date: 2007-09-17
Publication date: 2008-08-14
Also published as: AU2007346101A1; EP2061907B1; EP2061907A4; JP5426383B2; ES2374446T3; WO2008097277A2; JP2010503420A; US8071292B2; JP2014113146A; US20100004322A1; ATE534752T1; AU2007346101B2; WO2008097277A3; EP2061907A2; CN101535505A

Abstract

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of chronic lymphocytic leukemia (CLL). The invention also provides methods of identifying anti-CLL agents.

Description

TITLE
TCLI EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA
(CLL) REGULATED BY miR-29 AND miR-181 CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] N/A

GOVERNMENT SUPPORT

[0002] This invention was supported, in whole or in part, by grants from NIH
Grant/Contract Number PO1 CA81534. The Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

[0003] Chronic lymphocytic leukemia (B-CLL) is the most common human leukemia in the world accounting for approximately 10,000 new cases each year in the United States.' The TCLI (T-cell leukemia/lymphoma 1) oncogene was discovered as a target of frequent chromosomal rearrangements at 14q31.2 in mature T-cell leukemias.2 Previously it was reported that transgenic mice expressing TCLI in B-cells develop B-CLL.3 The inventor herein now believes that deregulation of TCLI may be a causal event in the pathogenesis.of B-CLL since the inventor has now also shown that TCLI is a co-activator of the Alct oncoprotein, a critical molecule in the transduction of anti-apoptotic signals in B- and T-cells 4 [0004] A recent report suggested that high TCLI expression in human CLL
correlates with unmutated VH status and ZAP70 positivity suggesting that TCL1-driven CLL is an aggressive form of B-CLL.5 One of the most significant genetic factors associated with poor prognosis in human B-CLL is the chromosome 1 I q deletion.6.

[0005] MicroRNAs are a large family of highly conserved non-coding genes thought to be involved in temporal and tissue specific gene regulation.7 We recently demonstrated that microRNA expression profiles can be used to distinguish normal B-cells from malignant B-CLL cells and that microRNA signatures are associated with prognosis and progression of chronic lymphocytic leukemia.8'9 [0006] No universally successful method for the treatment or prevention of B-CLL is currently available. The course of treatment for is often selected based on a variety of prognostic parameters including an analysis of specific tumor markers.
[0007] In spite of considerable research into therapies for B-CLL, CLL remains difficult to diagnose and treat effectively, and the mortality observed in patients indicates that improvements are needed in the diagnosis, treatment and prevention of the disease.
SUMMARY OF THE INVENTION

[0008] The present invention is based, in part, on the identification of a chronic lymphocytic leukemia cancer-specific signature of miRNAs that are differentially-expressed in breast cancer cells, relative to normal control cells.

[0009] Accordingly, the invention encompasses methods of diagnosing whether a subject has, or is at risk for developing, chronic lymphocytic leukemia (B-CLL), comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, B-CLL.

[0010] In certain embodiments, at least one miR gene product is miR-29 or miR-181. In certain embodiments, the at least one miR gene product is miR-29b and/or miR-181b.

[0011] The level of the at least one miR gene product can be measured using a variety of techniques that are well known to those of skill in the art. In one embodiment, the level of the at least one miR gene product is measured using Northern blot analysis. In another embodiment, the level of the at least one miR gene product in the test sample is less than the level ofthe corresponding miR gene product in the control sample. Also, in another embodiment, the level of the at least one miR
gene product in the test sample can be greater than the level of the corresponding miR gene product in the control sample.

[0012] The invention also provides methods of diagnosing a B-CLL associated with one or more prognostic markers in a subject, comprising measuring the level of at least one miR gene product in a B-CLL sample from said subject, wherein an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject having a B-CLL associated with the one or more prognostic markers. In one embodiment, the level of the at least one miR gene product is measured by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides; hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample; and, comparing the test sample hybridization profile to a hybridization profile generated from a control sample. An alteration in the signal of at least one miRNA is indicative of the subject either having, or being at risk for developing, B-CLL.

[0013] The invention also encompasses methods of treating CLL in a subject, wherein the signal of at least one miRNA, relative to the signal generated from the control sample, is de-regulated (e.g., down-regulated, up-regulated).

[0014] In certain embodiments, a microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR-29 or miR-181 and combinations thereof.

[0015] The invention also encompasses methods of diagnosing whether a subject has, or is at risk for developing, a B-CLL associated with one or more adverse prognostic markers in a subject, by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for said test sample; and, comparing the test sample hybridization profile to a hybridization profile generated from a control sample. An alteration in the signal is indicative of the subject either having, or being at risk for developing, the cancer.

[0016] The invention also encompasses methods of treating B-CLL in a subject who has a B-CLL in which at least one miR gene product is down-regulated or up-regulated in the cancer cells of the subject relative to control cells. When the at least one miR gene product is down-regulated in the cancer cells, the method comprises administering to the subject an effective amount of at least one isolated miR
gene product, such that proliferation of cancer cells in the subject is inhibited.
When the at least one miR gene product is up-regulated in the cancer cells, the method comprises administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, such that proliferation of cancer cells in the subject is inhibited. In certain embodiments, the at least one isolated miR gene product is selected miR-29, miR-181 and combinations thereof.

[0017] In related embodiments, the invention provides methods of treating B-CLL in a subject, comprising: determining the amount of at least one miR gene product in B-CLL cells, relative to control cells; and altering the amount of miR gene product expressed in the B-CLL cells by: administering to the subject an effective amount of at least one isolated miR gene product, if the amount of the miR gene product expressed in the cancer cells is less than the amount of the miR gene product expressed in control cells; or administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, if the amount of the miR
gene product expressed in the cancer cells is greater than the amount of the miR gene product expressed in control cells, such that proliferation of cancer cells in the subject is inhibited. In certain embodiments, at least one isolated miR gene product is selected from the group consisting of miR-29, miR-181, and combinations thereof.

[0018] The invention further provides pharmaceutical compositions for treating B-CLL, comprising at least one isolated miR gene product and a pharmaceutically-acceptable carrier. In a particular embodiment, the pharmaceutical compositions the at least one isolated miR gene product corresponds to a miR gene product that is down-regulated in B-CLL cells relative to suitable control cells. In particular embodiments, the pharmaceutical composition is selected from the group consisting of miR-29, miR-181 and combinations thereof. In another particular embodiment, the pharmaceutical composition comprises at least one miR expression inhibitor compound and a pharmaceutically-acceptable carrier. Also, in a particular embodiment, the pharmaceutical composition comprises at least one miR expression inhibitor compound.
is specific for a miR gene product that is up-regulated in B-CLL cells relative to suitable control cells.

[0019] In other embodiments, the present invention provides methods of identifying an anti-B-CLL agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in B-CLL cells, wherein an increase in the level of the miR
gene product in the cell, relative to a suitable control cell, is indicative of the test agent being an anti-B-CLL agent. In certain embodiments, the miR gene product is selected from the group consisting of miR-29, miR- 181 and combinations thereof.

[0020] The present invention also provides methods of identifying an anti-B-CLL agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in B-CLL cells, wherein an decrease in the level of the miR gene product in the cell, relative to a suitable control cell, is indicative of the test agent being an anti-B-CLL
agent. In a particular embodiment, the miR gene product is selected from the group consisting of miR-29, miR-181 and combinations thereof.

[0021] Various objects and advantages of this invention will become apparent to those skilled in the art from the following detailed description of the preferred embodiment, when read in light of the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figures 1 a-1 If TCLI expression is regulated by miR29 and miR18 [0023] Fig. la - TCLI expression on CLL. Lanes 1-8, CLL samples. Lanes 2 and 6: TCLI expression was rated as low. All other lines TCLI expression was rated as high to very high.

[0024] Fig. lb - TCL1 expression in three groups of B-CLL. Bars represent relative number of indicated B-CLL samples.

[0025] Fig. lc - Sequence alignment of miR-29b and miR-181b and 3' UTR of TCLI.

[0026] Fig. ld - miR-29 and miR-181 target TCLI expression in luciferase assays. For miR-29 luciferase assays a fragment of TCL1 cDNA including a region complimentary to miR-29 (Tcll) was inserted using the XbaI site immediately downstream from the stop codon of luciferase into pGL3 vector (Promega, Madison, WI) construct containing or pGL3 vector alone as indicated. For miR-181 assays full length TCLI cDNA was inserted into pGL3 vector in sense (TcI1FL) or anti sense (Tc11FLAS) orientation. 293 cells were co-transfected with the miR-29b or scramble negative control, as indicated, and pGL3 construct containing a part of TCLI
cDNA
including a region homologous to miR-29 (Tcll) or pGL3 vector alone as indicated.
For miR-181 assays TCLIFL or TCLIFLAS were co-transfected with miR-181.
Firefly and renilla luciferase activities were assayed with the dual luciferase assay system (Promega) and firefly luciferase activity was normalized to renilla luciferase activity, as suggested by manufacturer. All experiments were carried out in triplicate.

[0027] Fig. le -Effect of miR-29b and miR-181b on TCLI protein expression.
293 cells were transfected with pcDNA3TCLl.f1(a mammalian expression vector containing full length TCLI cDNA) alone (lane 1) or co-transfected with pcDNA3TCLIJI and miR-29b (lane 2) pre-miR negative control (lane 3) or miR-181b (lane 4). TCL1 expression was detected by Western blot using anti- TCLI
antibody.

[0028] Fig. 1 f- Correlation of TCL1 protein expression with miR-181b and miR-29b by microarray. The values represent microRNA microarray hybridization signal.

[0029] Figs. 2a and 2b - Real time RT-PCR analysis of representative CLL
samples. Three samples with high expression (25, 37 and 41) and four samples with low expression (55, 56, 72 and 81) of both miR-181 and miR-29 were chosen.
Real time RT-PCR analysis (ABI) was carried out for miR-181a, miR-181b, miR-181c, miR-181d, miR-29a, miR-29b and miR-29c according to manufacturer's protocol. All experiments were carried out in triplicate.

[0030] Fig. 3 contains Table 1 showing the statistically significant microRNAs differentiating CLL subtypes.

[0031] Figs. 4a -4d contain CLL sample information: Fig. 4a contains CLL
Sample Information; Fig. 4b contains aggressive CLL information; Fig. 4c contains indolent CLL information; and Fig. 4d contains aggressive CLL with 1 lq del.
The measurement of the mutational status of the expressed IgVH genes and immunophenotyping for ZAP-70 was performed as previously described (Rassenti LZ, Huynh L, Toy TL, et al. N Engl. J. Med. 2004; 351:893-901). FISH was performed using the conventional Vysis probes for the CLL panel. These FISH assays can detect the following chromosome anomalies (sets of probes): 1 lq- and 17p- (ATM at I
1q23 and P53 at 17p13.1), 13q- and trisomy 12 (D13S319 at 13q14, LAMPI at 13q34 and D 12Z3 at centromere 12.

[0032] Fig. 5 contains Table 2 showing the pairwise comparison microRNA
expression in three types of B-CLL.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0033] The current invention demonstrates that deregulation of the TCLI
oncogene is a causal event in the pathogenesis of the aggressive form of this disease, as was verified by using animal models. To study the mechanism of TCLI regulation in CLL, out microRNA expression profiling of three types of CLL was carried out:
indolent CLL, aggressive CLL and aggressive CLL showing I lq deletion.
Distinct microRNA signatures corresponding to each group of CLL were identified. It was further determined that TCLI expression is regulated by miR-29 and miR-181, two microRNAs differentially expressed in CLL. Expression levels of miR-29 and miR-generally inversely correlated with TCL1 expression in CLL samples that were examined. It is shown herein that TCLI expression in CLL is, at least in part, regulated by miR-29 and miR-181 and that these miRNAs may be candidates for therapeutic agents in CLLs overexpressing TCL1.

[0034] As used herein interchangeably, a "miR gene product," "microRNA,"
"miR," or "miRNA" refers to the unprocessed or processed RNA transcript from an miR gene. As the miR gene products are not translated into protein, the term "miR
gene products" does not include proteins. The unprocessed miR gene transcript is also called an "miR precursor," and typically comprises an RNA transcript of about nucleotides in length. The miR precursor can be processed by digestion with an RNAse (for example, Dicer, Argonaut, or RNAse III, e.g., E. coli RNAse III)) into an active 19-25 nucleotide RNA molecule. This active 19-25 nucleotide RNA
molecule is also called the "processed" miR gene transcript or "mature" miRNA.

[0035] The active 19-25 nucleotide RNA molecule can be obtained from the miR precursor through natural processing routes (e.g., using intact cells or cell lysates) or by synthetic processing routes (e.g., using isolated processing enzymes, such as isolated Dicer, Argonaut, or RNAase III). It is understood that the active 19-nucleotide RNA molecule can also be produced directly by biological or chemical synthesis, without having been processed from the miR precursor.

[0036] The present invention encompasses methods of diagnosing whether a subject has, or is at risk for developing, CLL, comprising measuring the level of at least one miR gene product in a test sample from the subject and comparing the level of the miR gene product in the test sample to the level of a corresponding miR gene product in a control sample. As used herein, a "subject" can be any mammal that has, or is suspected of having, breast cancer. In a particular embodiment, the subject is a human who has, or is suspected of having, CLL

[0037] The level of at least one miR gene product can be measured in cells of a 7 .

biological sample obtained from the subject. For example, a tissue sample can be removed from a subject suspected of having CLL associated with by conventional biopsy techniques. In another example, a blood sample can be removed from the subject, and white blood cells can be isolated for DNA extraction by standard techniques. The blood or tissue sample is preferably obtained from the subject prior to initiation of radiotherapy, chemotherapy or other therapeutic treatment. A
corresponding control tissue or blood sample can be obtained from unaffected tissues of the subject, from a normal human individual or population of normal individuals, or from cultured cells corresponding to the majority of cells in the subject's sample. The control tissue or blood sample is then processed along with the sample from the subject, so that the levels of miR gene product produced from a given miR gene in cells from the subject's sample can be compared to the corresponding miR gene product levels from cells of the control sample.

[0038] An alteration (i.e., an increase or decrease) in the level of a miR
gene product in the sample obtained from the subject, relative to the level of a corresponding miR gene product in a control sample, is indicative of the presence of CLL in the subject. In one embodiment, the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample (i.e., expression of the miR gene product is "up-regulated"). As used herein, expression of an miR gene product is "up-regulated" when the amount of miR
gene product in a cell or tissue sample from a subject is greater than the amount the same gene product in a control cell or tissue sample. In another embodiment, the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample (i.e., expression of the miR gene product is "down-regulated"). As used herein, expression of an miR gene is "down-regulated" when the amount of miR gene product produced from that gene in a cell or tissue sample from a subject is less than the amount produced from the same gene in a control cell or tissue sample. The relative miR gene expression in the control and normal samples can be determined with respect to one or more RNA expression standards. The standards can comprise, for example, a zero miR gene expression level, the miR gene expression level in a standard cell line, or the average level of miR gene expression previously obtained for a population of normal human controls.

[0039] The level of a miR gene product in a sample can be measured using any technique that is suitable for detecting RNA expression levels in a biological sample.
Suitable techniques for determining RNA expression levels in cells from a biological sample (e.g., Northern blot analysis, RT-PCR, in situ hybridization) are well known to those of skill in the art. In a particular embodiment, the level of at least one miR gene product is detected using Northern blot analysis. For example, total cellular RNA can be purified from cells by homogenization in the presence of nucleic acid extraction buffer, followed by centrifugation. Nucleic acids are precipitated, and DNA is removed by treatment with DNase and precipitation. The RNA molecules are then separated by gel electrophoresis on agarose gels according to standard techniques, and transferred to nitrocellulose filters. The RNA is then immobilized on the filters by heating. Detection and quantification of specific RNA is accomplished using appropriately labeled DNA or RNA probes complementary to the RNA in question.
See, for example, Molecular Cloning: A Laboratory Manual, J. Sambrook et al., eds., 2nd edition, Cold Spring Harbor Laboratory Press, 1989, Chapter 7, the entire disclosure of which is incorporated by reference.

[0040] Suitable probes for Northern blot hybridization of a given miR gene product can be produced from the nucleic acid sequences of the given miR.
Methods for preparation of labeled DNA and RNA probes, and the conditions for hybridization thereof to target nucleotide sequences, are described in Molecular Cloning: A
Laboratory Manual, J. Sambrook et al., eds., 2nd edition, Cold Spring Harbor Laboratory Press, 1989, Chapters 10 and 11, the disclosures of which are incorporated herein by reference.

[0041] For example, the nucleic acid probe can be labeled with, e.g., a radionuclide, such as 3H, 32P, 33P, 14C, or 35S; a heavy metal; or a ligand capable of functioning as a specific binding pair member for a labeled ligand (e.g., biotin, avidin or an antibody), a fluorescent molecule, a chemiluminescent molecule, an enzyme or the like.

[0042] Probes can be labeled to high specific activity by either the nick translation method of Rigby et al. (1977), J. Mol. Biol. 113:237-251 or by the random priming method of Fienberg et al. (1983), Anal. Biochem. 132:6-13, the entire disclosures of which are incorporated herein by reference. The latter is the method of choice for synthesizing 32P-labeled probes of high specific activity from single-stranded DNA or from RNA templates. For example, by replacing preexisting nucleotides with highly radioactive nucleotides according to the nick translation method, it is possible to prepare 32P-labeled nucleic acid probes with a specific activity well in excess of 108 cpm/microgram. Autoradiographic detection of hybridization can then be performed by exposing hybridized filters to photographic film. Densitometric scanning of the photographic films exposed by the hybridized filters provides an accurate measurement of miR gene transcript levels. Using another approach, miR gene transcript levels can be quantified by computerized imaging systems, such the Molecular Dynamics 400-B
2D Phosphorimager available from Amersham Biosciences, Piscataway, NJ.

[0043] Where radionuclide labeling of DNA or RNA probes is not practical, the random-primer method can be used to incorporate an analogue, for example, the dTTP
analogue 5-(N-(N-biotinyl-epsilon-aminocaproyl)-3-aminoallyl)deoxyuridine triphosphate, into the probe molecule. The biotinylated probe oligonucleotide can be detected by reaction with biotin-binding proteins, such as avidin, streptavidin, and antibodies (e.g., anti-biotin antibodies) coupled to fluorescent dyes or enzymes that produce color reactions.

[0044] In addition to Northern and other RNA hybridization techniques, determining the levels of RNA transcripts can be accomplished using the technique of in situ hybridization. This technique requires fewer cells than the Northern blotting technique, and involves depositing whole cells onto a microscope cover slip and probing the nucleic acid content of the cell with a solution containing radioactive or otherwise labeled nucleic acid (e.g., cDNA or RNA) probes. This technique is particularly well-suited for analyzing tissue biopsy samples from subjects.
The practice of the in situ hybridization technique is described in more detail in U.S.
Pat. No.
5,427,916, the entire disclosure of which is incorporated herein by reference.
Suitable probes for in situ hybridization of a given miR gene product can be produced from the nucleic acid sequences.

[0045] The relative number of miR gene transcripts in cells can also be determined by reverse transcription of miR gene transcripts, followed by amplification of the reverse-transcribed transcripts by polymerase chain reaction (RT-PCR).
The levels of miR gene transcripts can be quantified in comparison with an internal standard, for example, the level of mRNA from a "housekeeping" gene present in the same sample. A suitable "housekeeping" gene for use as an internal standard includes, e.g., myosin or glyceraldehyde-3-phosphate dehydrogenase (G3PDH). The methods for quantitative RT-PCR and variations thereof are within the skill in the art.

[0046] In some instances, it may be desirable to simultaneously determine the expression level of a plurality of different miR gene products in a sample. In other instances, it may be desirable to determine the expression level of the transcripts of all known miR genes correlated with a cancer. Assessing cancer-specific expression levels for hundreds of miR genes is time consuming and requires a large amount of total RNA
(at least 20 g for each Northern blot) and autoradiographic techniques that require radioactive isotopes.

[0047] To overcome these limitations, an oligolibrary, in microchip format (i.e., a microarray), may be constructed containing a set of probe oligodeoxynucleotides that are specific for a set of miR genes. Using such a microarray, the expression level of multiple microRNAs in a biological sample can be determined by reverse transcribing the RNAs to generate a set of target oligodeoxynucleotides, and hybridizing them to probe oligodeoxynucleotides on the microarray to generate a hybridization, or expression, profile. The hybridization profile of the test sample can then be compared to that of a control sample to determine which microRNAs have an altered expression level in CLL. As used herein, "probe oligonucleotide" or "probe oligodeoxynucleotide"
refers to ari oligonucleotide that is capable of hybridizing to a target oligonucleotide.
"Target oligonucleotide" or "target oligodeoxynucleotide" refers to a molecule to be detected (e.g., via hybridization). By "miR-specific probe oligonucleotide" or "probe oligonucleotide specific for an miR" is meant a probe oligonucleotide that has a sequence selected to hybridize to a specific miR gene product, or to a reverse transcript of the specific miR gene product.

[0048] An "expression profile" or "hybridization profile" of a particular sample is essentially a fingerprint of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell.
That is, normal cells may be distinguished from CLL cells, and within CLL
cells, different prognosis states (good or poor long term survival prospects, for example) may be determined. By comparing expression profiles of CLL cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. The identification of sequences that are differentially expressed in CLL cells or normal cells, as well as differential expression resulting in different prognostic outcomes, allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated (e.g., to determine whether a chemotherapeutic drug act to improve the long-term prognosis in a particular patient). Similarly, diagnosis may be done or confirmed by comparing patient samples with the known expression profiles. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates that suppress the CLL expression profile or convert a poor prognosis profile to a better prognosis profile.

[0049] Accordingly, the invention provides methods of diagnosing whether a subject has, or is at risk for developing, CLL, comprising reverse transcribing RNA
from a test sample obtained from the subject to provide a set of target oligo-deoxynucleotides, hybridizing the target oligo-deoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample, and comparing the test sample hybridization profile to a hybridization profile generated from a control sample, wherein an alteration in the signal of at least one miRNA is indicative of the subject either having, or being at risk for developing, CLL.

[0050] In one embodiment, the microarray comprises miRNA-specific probe oligonucleotides for a substantial portion of the human miRNome. In a particular embodiment, the microarray comprises miRNA-specific probe oligo-nucleotides for one or more miRNAs selected from the group consisting of miR-29 or miR-181 and combinations thereof.

[0051] The microarray can be prepared from gene-specific oligonucleotide probes generated from known miRNA sequences. The array may contain two different oligonucleotide probes for each miRNA, one containing the active, mature sequence and the other being specific for the precursor of the miRNA. The'array may also contain controls, such as one or more mouse sequences differing from human orthologs by only a few bases, which can serve as controls for hybridization stringency conditions. tRNAs from both species may also be printed on the microchip, providing an internal, relatively stable, positive control for specific hybridization.
One or more appropriate controls for non-specific hybridization may also be included on the microchip. For this purpose, sequences are selected based upon the absence of any homology with any known miRNAs.

[0052] The microarray may be fabricated using techniques known in the art.
For example, probe oligonucleotides of an appropriate length, e.g., 40 nucleotides, are 5'-amine modified at position C6 and printed using commercially available microarray systems, e.g., the GeneMachine OmniGridTM 100 Microarrayer and Amersham CodeLinkTM activated slides. Labeled cDNA oligomer corresponding to the target RNAs is prepared by reverse transcribing the target RNA with labeled primer.
Following first strand synthesis, the RNA/DNA hybrids are denatured to degrade the RNA templates. The labeled target cDNAs thus prepared are then hybridized to the microarray chip under hybridizing conditions, e.g., 6X SSPE/30% formamide at for 18 hours, followed by washing in 0.75X TNT at 37 C for 40 minutes. At positions on the array where the immobilized probe DNA recognizes a complementary target cDNA in the sample, hybridization occurs. The labeled target cDNA marks the exact position on the array where binding occurs, allowing automatic detection and quantification. The output consists of a list of hybridization events, indicating the relative abundance of specific cDNA sequences, and therefore the relative abundance of the corresponding complementary miRs, in the patient sample. According to one embodiment, the labeled cDNA oligomer is a biotin-labeled cDNA, prepared from a biotin-labeled primer. The microarray is then processed by direct detection of the biotin-containing transcripts using, e.g., Streptavidin-Alexa647 conjugate, and scanned utilizing conventional scanning methods. Image intensities of each spot on the array are proportional to the abundance of the corresponding miR in the patient sample.

[0053] The use of the array has several advantages for miRNA expression detection. First, the global expression of several hundred genes can be identified in the same sample at one time point. Second, through careful design of the oligonucleotide probes, expression of both mature and precursor molecules can be identified.
Third, in comparison with Northern blot analysis, the chip requires a small amount of RNA, and provides reproducible results using 2.5 g of total RNA. The relatively limited number of miRNAs (a few hundred per species) allows the construction of a common microarray for several species, with distinct oligonucleotide probes for each.
Such a tool would allow for analysis of trans-species expression for each known miR
under various conditions.

[0054] In addition to use for quantitative expression level assays of specific miRs, a microchip containing miRNA-specific probe oligonucleotides corresponding to a substantial portion of the miRNome, preferably the entire miRNome, may be employed to carry out miR gene expression profiling, for analysis of miR
expression patterns. Distinct miR signatures can be associated with established disease markers, or directly with a disease state.

[0055] According to the expression profiling methods described herein, total RNA from a sample from a subject suspected of having a cancer (e.g., CLL) is quantitatively reverse transcribed to provide a set of labeled target oligodeoxynucleotides complementary to the RNA in the sample. The target oligodeoxynucleotides are then hybridized to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the sample. The result is a hybridization profile for the sample representing the expression pattern of miRNA in the sample. 'The hybridization profile comprises the signal from the binding of the target oligodeoxynucleotides from the sample to the miRNA-specific probe oligonucleotides in the microarray. The profile may be recorded as the presence,or absence of binding (signal vs. zero signal). More preferably, the profile recorded includes the intensity of the signal from each hybridization. The profile is compared to the hybridization profile generated from a normal, i.e., noncancerous, control sample.
An alteration in the signal is indicative of the presence of the cancer in the subject.

[0056] Other techniques for measuring miR gene expression are also within the-skill in the art, and include various techniques for measuring rates of RNA
transcription and degradation.

[0057] The invention also provides methods of diagnosing a CLL associated with one or more prognostic markers, comprising measuring the level of at least one miR gene product in a CLL test sample from a subject and comparing the level of the at least one miR gene product in the CLL test sample to the level of a corresponding miR
gene product in a control sample. An alteration (e.g., an increase, a decrease) in the signal of at least one miRNA in the test sample relative to the control sample is indicative of the subject either having, or being at risk for developing, CLL
associated with the one or more prognostic markers.

[0058] The CLL can be associated with one or more prognostic markers or features, including, a marker associated with an adverse (i.e., negative) prognosis, or a marker associated with a good (i.e., positive) prognosis. In certain embodiments, the CLL that is diagnosed using the methods described herein is associated with one or more adverse prognostic features.

[0059] Particular microRNAs whose expression is altered in CLL cells associated with each of these prognostic inarkers are described herein. In one embodiment, the level of the at least one miR gene product is measured by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides, hybridizing the target oligodeoxynucleotides to a microarray that comprises miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample, and comparing the test sample hybridization profile to a hybridization profile generated from a control sample.

[0060] Without wishing to be bound by any one theory, it is believed that alterations in the level of one or more miR gene products in cells can result in the deregulation of one or more intended targets for these miRs, which can lead to the formation of CLL. Therefore, altering the level of the miR gene product (e.g., by decreasing the level of a miR that is up-regulated,in CLL cells, by increasing the level of a miR that is down-regulated in cancer cells) may successfully treat the CLL.
Examples of putative gene targets for miRNAs that are deregulated in CLL cells are described herein.

[0061] Accordingly, the present invention encompasses methods of treating CLL in a subject, wherein at least one miR gene product is de-regulated (e.g., down-regulated, up-regulated) in the cancer cells of the subject. When the at least one isolated miR gene product is down-regulated in the CLL cells, the method comprises administering an effective amount of the at least one isolated miR gene product such that proliferation of cancer cells in the subject is inhibited. When the at least one isolated miR gene product is up-regulated in the cancer cells, the method comprises administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene, referred to herein as miR gene expression inhibition compounds, such that proliferation of CLL cells is inhibited.

[0062] The terms "treat", "treating" and "treatment", as used herein, refer to ameliorating symptoms associated with a disease or condition, for example, CLL, including preventing or delaying the onset of the disease symptoms, and/or lessening the severity or frequency of symptoms of the disease or condition. The terms "subject"
and "individual" are defined herein to include animals, such as mammals, including but not limited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice or other bovine, ovine, equine, canine, feline, rodent, or murine species. In a preferred embodiment, the animal is a human.

[0063] As used herein, an "effective amount" of an isolated miR gene product is an amount sufficient to inhibit proliferation of a cancer cell in a subject suffering from CLL. One skilled in the art can readily determine an effective amount of an miR
gene product to be administered to a given subject, by taking into account factors, such as the size and weight of the subject; the extent of disease penetration; the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic.

[0064] For example, an effective amount of an isolated miR gene product can be based on the approximate or estimated body weight of a subject to be treated.
Preferably, such effective amounts are administered parenterally or enterally, as described herein. For example, an effective amount of the isolated miR gene product is administered to a subject can range from about 5 - 3000 micrograms/kg of body weight, from about 700 - 1000 micrograms/kg of body weight, or greater than about 1000 micrograms/kg of body weight.

[0065] One skilled in the art can also readily determine an appropriate dosage regimen for the administration of an isolated miR gene product to a given subject. For example, an miR gene product can be administered to the subject once (e.g., as a single injection or deposition). Alternatively, an miR gene product can be administered once or twice daily to a subject for a period of from about three to about twenty-eight days, more particularly from about seven to about ten days. In a particular dosage regimen, an miR gene product is administered once a day for seven days. Where a dosage regimen comprises multiple administrations, it is understood that the effective amount of the miR gene product administered to the subject can comprise the total amount of gene product administered over the entire dosage regimen.

[0066] As used herein, an "isolated" miR gene product is one which is synthesized, or altered or removed from the natural state through human intervention.
For example, a synthetic miR gene product, or an miR gene product partially or completely separated from the coexisting materials of its natural state, is considered to be "isolated." An isolated miR gene product can exist in substantially-purified form, or can exist in a cell into which the miR gene product has been delivered. Thus, an miR
gene product which is deliberately delivered to, or expressed in, a cell is considered an "isolated" miR gene product. An miR gene product produced inside a cell from an miR
precursor molecule is also considered to be "isolated" molecule.

[0067] Isolated miR gene products can be obtained using a number of standard techniques. For example, the miR gene products can be chemically synthesized or recombinantly produced using methods known in the art. In one embodiment, miR
gene products are chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer. Commercial suppliers of synthetic RNA molecules or synthesis reagents include, e.g., Proligo (Hamburg, Germany), Dharmacon Research (Lafayette, CO, U.S.A.), Pierce Chemical (part of Perbio Science, Rockford, IL, U.S.A.), Glen Research (Sterling, VA, U.S.A.), ChemGenes (Ashland, MA, U.S.A.) and Cruachem (Glasgow, UK).

[0068] Alternatively, the miR gene products can be expressed from recombinant circular or linear DNA plasmids using any suitable promoter.
Suitable promoters for expressing RNA from a plasmid include, e.g., the U6 or HI RNA
po1 III
promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art. The recombinant plasmids of the invention can also comprise inducible or regulatable promoters for expression of the miR
gene products in cancer cells.

[0069] The miR gene products that are expressed from recombinant plasmids can be isolated from cultured cell expression systems by standard techniques.
The miR
gene products which are expressed from recombinant plasmids can also be delivered to, and expressed directly in, the cancer cells. The use of recombinant plasmids to deliver the miR gene products to cancer cells is discussed in more detail below.

[0070] The miR gene products can be expressed from a separate recombinant plasmid, or they can be expressed from the same recombinant plasmid. In one embodiment, the miR gene products are expressed as RNA precursor molecules from a single plasmid, and the precursor molecules are processed into the functional miR gene product by a suitable processing system, including, but not limited to, processing systems extant within a cancer cell. Other suitable processing systems include, e.g., the in vitro Drosophila cell lysate system (e.g., as described in U.S. Published Patent Application No. 2002/0086356 to Tuschl et al., the entire disclosure of which are incorporated herein by reference) and the E. coli RNAse III system (e.g., as described in U.S. Published Patent Application No. 2004/00 1 4 1 1 3 to Yang et al., the entire disclosure of which are incorporated herein by refereiice).

[0071] Selection of plasmids suitable for expressing the miR gene products, methods for inserting nucleic acid sequences into the plasmid to express the gene products, and methods of delivering the recombinant plasmid to the cells of interest are within the skill in the art. See, for example, Zeng et al. (2002), Molecular Ce119:1327-1333; Tuschl (2002), Nat. Biotechnol, 20:446-448; Brummelkamp et al. (2002), Science 296:550-553; Miyagishi et al. (2002), Nat. Biotechnol. 20:497-500;
Paddison et al. (2002), Genes Dev. 16:948-958; Lee et al. (2002), Nat. Biotechnol.
20:500-505;
and Paul et al. (2002), Nat. Biotechnol. 20:505-508, the entire disclosures of which are incorporated herein by reference.

[0072] In one embodiment, a plasmid expressing the miR gene products comprises a sequence encoding a miR precursor RNA under the control of the CMV
intermediate-early promoter. As used herein, "under the control" of a promoter means that the nucleic acid sequences encoding the miR gene product are located 3' of the promoter, so that the promoter can initiate transcription of the miR gene product coding sequences.

[0073] The miR gene products can also be expressed from recombinant viral vectors. It is contemplated that the miR gene products can be expressed from two separate recombinant viral vectors, or from the same viral vector. The RNA
expressed from the recombinant viral vectors can either be isolated from cultured cell expression systems by standard techniques, or can be expressed directly in cancer cells.
The use of recombinant viral vectors to deliver the miR gene products to cancer cells is discussed in more detail below.

[0074] The recombinant viral vectors of the invention comprise sequences encoding the miR gene products and any suitable promoter for expressing the RNA.
sequences. Suitable promoters include, for example, the U6 or HI RNA pol III
promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the miR
gene products in a cancer cell.

[0075] Any viral vector capable of accepting the coding sequences for the miR
gene products can be used; for example, vectors derived from adenovirus (AV);
adeno-associated virus (AAV); retroviruses (e.g., lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like. The tropism of the viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate.

[0076] For example, lentiviral vectors of the invention can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors of the invention can be made to target different cells by engineering the vectors to express different capsid protein serotypes. For example, an AAV
vector expressing a serotype 2 capsid on a serotype 2 genome is called AAV 2/2. This serotype 2 capsid gene in the AAV 2/2 vector can be replaced by a serotype 5 capsid gene to produce an AAV 2/5 vector. Techniques for constructing AAV vectors that express different capsid protein serotypes are within the skill in the art;
see, e.g., Rabinowitz, J.E., et al. (2002), J. Virol. 76:791-801, the entire disclosure of which is incorporated herein by reference.

[0077] Selection of recombinant viral vectors suitable for use in the invention, methods for inserting nucleic acid sequences for expressing RNA into the vector, methods of delivering the viral vector to the cells of interest, and recovery of the expressed RNA products are within the skill in the art. See, for example, Dornburg (1995), Gene Therap. 2:301-310; Eglitis (1988), Biotechniques 6:608-614;
Miller (1990), Hum. Gene Therap. 1:5-14; and Anderson (1998), Nature 392:25-30, the entire disclosures of which are incorporated herein by reference.

[0078] Particularly suitable viral vectors are those derived from AV and AAV.
A suitable AV vector for expressing the miR gene products, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia et al. (2002), Nat. Biotech. 20:1006-1010, the entire disclosure of which is incorporated herein by reference. Suitable AAV vectors for expressing the miR gene products, methods for constructing the recombinant AAV vector, and methods for delivering the vectors into target cells are described in Samulski et al.
(1987), J. Virol. 61:3096-3101; Fisher et al. (1996), J. Virol., 70:520-532;
Samulski et al. (1989), J. Virol. 63:3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No.
5,139,941;
International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are incorporated herein by reference. In one embodiment, the miR gene products are expressed from a single recombinant AAV vector comprising the CMV intermediate early promoter.

[0079] In a certain embodiment, a recombinant AAV viral vector of the invention comprises a nucleic acid sequence encoding an miR precursor RNA in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter. As used herein, "in operable connection with a polyT
termination sequence" means that the nucleic acid sequences encoding the sense or antisense strands are immediately adjacent to the polyT termination signal in the 5' direction.
During transcription of the miR sequences from the vector, the polyT
termination signals act to terminate transcription.

[0080] In other embodiments of the treatment methods of the invention, an effective amount of at least one compound which inhibits miR expression can also be administered to the subject. As used herein, "inhibiting miR expression" means that the production of the active, mature form of miR gene product after treatment is less than the amount produced prior to treatment. One skilled in the art can readily determine whether miR expression has been inhibited in a cancer cell, using for example the techniques for determining miR transcript level discussed above for the diagnostic method. Inhibition can occur at the level of gene expression (i.e., by inhibiting transcription of a miR gene encoding the miR gene product) or at the level of processing (e.g., by inhibiting processing of a miR precursor into a mature, active miR).

[0081] As used herein,.an "effective amount" of a compound that inhibits miR
expression is an amount sufficient to inhibit proliferation of a cancer cell in a subject suffering from a cancer associated with a cancer-associated chromosomal feature. One skilled in the art can readily determine an effective amount of an miR
expression-inhibiting compound to be administered to a given subject, by taking into account factors, such as the size and weight of the subject; the extent of disease penetration;
the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic.

[0082] For example, an effective amount of the expression-inhibiting compound can be based on the approximate or estimated body weight of a subject to be treated. Such effective amounts are administered parenterally or enterally, among others, as described herein. For example, an effective amount of the expression-inhibiting compound administered to a subject can range from about 5-3000 micrograms/kg of body weight, from about 700 - 1000 micrograms/kg of body weight, or it can be greater than about 1000 micrograms/kg of body weight.

[0083] One skilled in the art can also readily determine an appropriate dosage regimen for administering a compound that inhibits miR expression to a given subject.
For example, an expression-inhibiting compound can be administered to the subject once (e.g., as a single injection or deposition). Alternatively, an expression-inhibiting compound can be administered once -or twice daily to a subject for a period of from about three to about twenty-eight days, more preferably from about seven to about ten days. In a particular dosage regimen, an expression-inhibiting compound is administered once a day for seven days. Where a dosage regimen comprises multiple administrations, it is understood that the effective amount of the expression-inhibiting compound administered to the subject can comprise the total amount of compound administered over the entire dosage regimen.

[0084] Suitable compounds for inhibiting miR gene expression include double-stranded RNA (such as short- or small-interfering RNA or "siRNA"), antisense nucleic acids, and enzymatic RNA molecules, such as ribozymes. Each of these compounds can be targeted to a given miR gene product and destroy or induce the destruction of the target miR gene product.

[0085] For example, expression of a given miR gene can be inhibited by inducing RNA interference of the miR gene with an isolated double-stranded RNA
("dsRNA") molecule which has at least 90%, for example at least 95%, at least 98%, at least 99% or 100%, sequence homology with at least a portion of the miR gene product.
In a particular embodiment, the dsRNA molecule is a "short or small interfering RNA"
or "siRNA."

[0086] siRNA useful in the present methods comprise short double-stranded RNA from about 17 nucleotides to about 29 nucleotides in length, preferably from about 19 to about 25 nucleotides in length. The siRNA comprise a sense RNA
strand and a complementary antisense RNA strand annealed together by standard Watson-Crick base-pairing interactions (hereinafter "base-paired"). The sense strand comprises a nucleic acid sequence which is substantially identical to a nucleic acid sequence contained within the target miR gene product.

[0087] As used herein, a nucleic acid sequence in an siRNA which is "substantially identical" to a target sequence contained within the target mRNA is a nucleic acid sequence that is identical to the target sequence, or that differs from the target sequence by one or two nucleotides. The sense and antisense strands of the siRNA can comprise two complementary, single-stranded RNA molecules, or can comprise a single molecule in which two complementary portions are base-paired and are covalently linked by a single-stranded "hairpin" area.

[0088] The siRNA can also be altered RNA that differs from naturally-occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siRNA or to one or more internal nucleotides of the siRNA, or modifications that make the siRNA resistant to nuclease digestion, or the substitution of one or more nucleotides in the siRNA with deoxyribonucleotides.

[0089] One or both strands of the siRNA can also comprise a 3' overhang. As used herein, a"3' overhang" refers to at least one unpaired nucleotide extending from the 3'-end of a duplexed RNA strand. Thus, in certain embodiments, the siRNA
comprises at least one 3' overhang of from 1 to about 6 nucleotides (which includes ribonucleotides or deoxyribonucleotides) in length, from I to about 5 nucleotides in length, from I to about 4 nucleotides in length, or from about 2 to about 4 nucleotides in length. In a particular embodiment, the 3' overhang is present on both strands of the siRNA, and is 2 nucleotides in length. For example, each strand of the siRNA
can comprise 3' overhangs of dithymidylic acid ("TT") or diuridylic acid ("uu").

[0090] The siRNA can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products. Exemplary methods for producing and testing dsRNA
or siRNA molecules are described in U.S. Published Patent Application No.
2002/0173478 to Gewirtz and in U.S. Published Patent Application No.

to Reich et al., the entire disclosures of which are incorporated herein by reference.

[0091] Expression of a given miR gene can also be inhibited by an antisense nucleic acid. As used herein, an "antisense nucleic acid" refers to a nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-peptide nucleic acid interactions, which alters the activity of the target RNA. Antisense nucleic acids suitable for use in the present methods are single-stranded nucleic acids (e.g., RNA, DNA, RNA-DNA chimeras, PNA) that generally comprise a nucleic acid sequence complementary to a contiguous nucleic acid sequence in an miR gene product. The antisense nucleic acid can comprise a nucleic acid sequence that is 50-100% complementary, 75-100% complementary, or 95-100% complementary to a contiguous nucleic acid sequence in an miR gene product. Nucleic acid sequences for the miR gene products are provided herein. Without wishing to be bound by any theory, it is believed that the antisense nucleic acids activate RNase H or another cellular nuclease that digests the miR gene product/antisense nucleic acid duplex.

[0092] Antisense nucleic acids can also contain modifications to the nucleic acid backbone or to the sugar and base moieties (or their equivalent) to enhance target specificity, nuclease resistance, delivery or other properties related to efficacy of the molecule. Such modifications include cholesterol moieties, duplex intercalators, such as acridine, or one or more nuclease-resistant groups.

[0093] Antisense nucleic acids can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products. Exemplary methods for producing and testing are within the skill in the art; see, e.g., Stein and Cheng (1993), Science 261:1004 and U.S. Pat.
No. 5,849,902 to Woolf et al., the entire disclosures of which are incorporated herein by reference.

[0094] Expression of a given miR gene can also be inhibited by an enzymatic nucleic acid. As used herein, an "enzymatic nucleic acid" refers to a nucleic acid comprising a substrate binding region that has complementarity to a contiguous nucleic acid sequence of an miR gene product, and which is able to specifically cleave the miR
gene product. The enzymatic nucleic acid substrate binding region can be, for example, 50-100% complementary, 75-100% complementary, or 95-100% complementary to a contiguous nucleic acid sequence in an miR gene product. The enzymatic nucleic acids can also comprise modifications at the base, sugar, and/or phosphate groups.
An exemplary enzymatic nucleic acid for use in the present methods is a ribozyme.

[0095] The enzymatic nucleic acids can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products. Exemplary methods for producing and testing dsRNA
or siRNA molecules are described in Werner and Uhlenbeck (1995), Nucl. Acids Res.
23:2092-96; Hammann et al. (1999), Antisense and Nucleic Acid Drug Dev. 9:25-31;
and U.S. Pat. No. 4,987,071 to Cech et al, the entire disclosures of which are incorporated herein by reference.

[0096] Administration of at least one miR gene product, or at least one compound for inhibiting miR expression, will inhibit the proliferation of cancer cells in a subject who has a cancer associated with a cancer-associated chromosomal feature.
As used herein, to "inhibit the proliferation of a cancer cell" means to kill the cell, or permanently or temporarily arrest or slow the growth of the cell. Inhibition of cancer cell proliferation can be inferred if the number of such cells in the subject remains constant or decreases after administration of the miR gene products or miR
gene expression-inhibiting compounds. An inhibition of cancer cell proliferation can also be inferred if the absolute number of such cells increases, but the rate of tumor growth decreases.

[0097] The number of cancer cells in a subject's body can be determined by direct measurement, or by estimation from the size of primary or metastatic tumor masses. For example, the number of cancer cells in a subject can be measured by immunohistological methods, flow cytometry, or other techniques designed to detect characteristic surface markers of cancer cells.

[0098] The miR gene products or miR gene expression-inhibiting compounds can be administered to a subject by any means suitable for delivering these compounds to cancer cells of the subject. For example, the miR gene products or miR
expression inhibiting compounds can be administered~ by methods suitable to transfect cells of the subject with these compounds, or with nucleic acids comprising sequences encoding these compounds. In one embodiment, the cells are transfected with a plasmid or viral vector comprising sequences encoding at least one miR gene product or miR gene expression inhibiting compound.

[0099] Transfection methods for eukaryotic cells are well known in the art, and include, e.g., direct injection of the nucleic acid into the nucleus or pronucleus of a cell;
electroporation; liposome transfer or transfer mediated by lipophilic materials;
receptor-mediated nucleic acid delivery, bioballistic or particle acceleration; calcium phosphate precipitation, and transfection mediated by viral vectors.

[00100] For example, cells can be transfected with a liposomal transfer compound, e.g., DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methylsulfate, Boehringer - Mannheim) or an equivalent, such as LIPOFECTIN.
The amount of nucleic acid used is not critical to the practice of the invention;
acceptable results may be achieved with 0.1-100 micrograms of nucleic acid/105 cells. For example, a ratio of about 0.5 micrograms of plasmid vector in 3 micrograms of DOTAP
per 105 cells can be used.

[00101] An miR gene product or miR gene expression inhibiting compound can also be administered to a subject by any suitable enteral or parenteral administration route. Suitable enteral administration routes for the present methods include, e.g., oral, rectal, or intranasal delivery. Suitable parenteral administration routes include, e.g., intravascular administration (e.g., intravenous bolus injection, intravenous infusion, intra-arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature); peri- and intra-tissue injection (e.g., peri-tumoral and intra-tumoral injection, intra-retinal injection, or subretinal injection); subcutaneous injection or deposition, including subcutaneous infusion (such as by osmotic pumps); direct application to the tissue of interest, for example by a catheter or other placement device (e.g., a retinal pellet or a suppository or an implant comprising a porous, non-porous, or gelatinous material); and inhalation. Particularly suitable administration routes are injection, infusion and intravenous administration into the patient.

[00102] In the present methods, an miR gene product or miR gene product expression inhibiting compound can be administered to the subject either as naked RNA, in combination with a delivery reagent, or as a nucleic acid (e.g., a recombinant plasmid or viral vector) comprising sequences that express the miR gene product or expression inhibiting compound. Suitable delivery reagents include, e.g., the Mirus Transit TKO lipophilic reagent; lipofectin; lipofectamine; cellfectin;
polycations (e.g., polylysine), and liposomes.

[00103] Recombinant plasmids and viral vectors comprising sequences that express the miR gene products or miR gene expression inhibiting compounds, and techniques for delivering such plasmids and vectors to cancer cells, are discussed herein.

[00104] In a particular embodiment, liposomes are used to deliver an miR gene product or miR gene expression-inhibiting compound (or nucleic acids comprising sequences encoding them) to a subject. Liposomes can also increase the blood half-life of the gene products or nucleic acids. Suitable liposomes for use in the invention can be formed from standard vesicle-forming lipids, which generally include neutral or negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of factors, such as the desired liposome size and half-life of the liposomes in the blood stream. A variety of methods are known for preparing liposomes, for example, as described in Szoka et al. (1980), Ann.
Rev.

Biophys. Bioeng. 9:467; and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, the entire disclosures of which are incorporated herein by reference.

[00105] The liposomes for use in the present methods can comprise a ligand molecule that targets the liposome to cancer cells. Ligands which bind to receptors prevalent in cancer cells, such as monoclonal antibodies that bind to tumor cell antigens, are preferred.

[00106] The liposomes for use in the present methods can also be modified so as to avoid clearance by the mononuclear macrophage system ("MMS") and reticuloendothelial system ("RES"). Such modified liposomes have opsonization-inhibition moieties on the surface or incorporated into the liposome structure. In a particularly preferred embodiment, a liposome of the invention can comprise both opsonization-inhibition moieties and a ligand.

[00107] Opsonization-inhibiting moieties for use in preparing the liposomes of the invention are typically large hydrophilic polymers that are bound to the liposome membrane. As used herein, an opsonization inhibiting moiety is "bound" to a liposome membrane when it is chemically or physically attached to the membrane, e.g., by the intercalation of a lipid-soluble anchor into the membrane itself, or by binding directly to active groups of membrane lipids. These opsonization-inhibiting hydrophilic polymers form a protective surface layer that significantly decreases the uptake of the liposomes by the MMS and RES; e.g., as described in U.S. Pat. No. 4,920,016, the entire disclosure of which is incorporated herein by reference.

[00108] Opsonization inhibiting moieties suitable for modifying liposomes are preferably water-soluble polymers with a number-average molecular weight from about 500 to about 40,000 daltons, and more preferably from about 2,000 to about 20,000 daltons. Such polymers include polyethylene glycol (PEG) or polypropylene glycol (PPG) derivatives; e.g., methoxy PEG or PPG, and PEG or PPG stearate;
synthetic polymers, such as polyacrylamide or poly N-vinyl pyrrolidone; linear, branched, or dendrimeric polyamidoamines; polyacrylic acids; polyalcohols, e.g., polyvinylalcohol and polyxylitol to which carboxylic or amino groups are chemically linked, as well as gangliosides, such as ganglioside GM1. Copolymers of PEG, methoxy PEG, or methoxy PPG, or derivatives thereof, are also suitable. In addition, the opsonization inhibiting polymer can be a block copolymer of PEG and either a polyamino acid, polysaccharide, polyamidoamine, polyethyleneamine, or polynucleotide. The opsonization inhibiting polymers can also be natural polysaccharides containing amino acids or carboxylic acids, e.g., galacturonic acid, glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid, neuraminic acid, alginic acid, carrageenan;
aminated polysaccharides or oligosaccharides (linear or branched); or carboxylated polysaccharides or oligosaccharides, e.g., reacted with derivatives of carbonic acids with resultant linking of carboxylic groups. Preferably, the opsonization-inhibiting moiety is a PEG, PPG, or derivatives thereof. Liposomes modified with PEG or PEG-derivatives are sometimes called "PEGylated liposomes."

[00109] The opsonization inhibiting moiety can be bound to the liposome membrane by any one of numerous well-known techniques. For example, an N-hydroxysuccinimide ester of PEG can be bound to a phosphatidyl-ethanolamine lipid-soluble anchor, and then bound to a membrane. Similarly, a dextran polymer can be derivatized with a stearylamine lipid-soluble anchor via reductive amination using Na(CN)BH3 and a solvent mixture, such as tetrahydrofuran and water in a 30:12 ratio at 60 C.

[00110] Liposomes modified with opsonization-inhibition moieties remain in the circulation much longer than unmodified liposomes. For this reason, such liposomes are sometimes called "stealth" liposomes. Stealth liposomes are known to accumulate in tissues fed by porous or "leaky" microvasculature. Thus, tissue characterized by such microvasculature defects, for example solid tumors, will efficiently accumulate these liposomes; see Gabizon, et al. (1988), Proc. Natl. Acad. Sci., U.S.A., 18:6949-53.
In addition, the reduced uptake by the RES lowers the toxicity of stealth liposomes by preventing significant accumulation of the liposomes in the liver and spleen.
Thus, liposomes that are modified with opsonization-inhibition moieties are particularly suited to deliver the miR gene products or miR gene expression inhibition compounds (or nucleic acids comprising sequences encoding them) to tumor cells.

[00111] The miR gene products or miR gene expression inhibition compounds can be formulated as pharmaceutical compositions, sometimes called "medicaments,"
prior to administering them to a subject, according to techniques known in the art.
Accordingly, the invention encompasses pharmaceutical compositions for treating CLL. In one embodiment, the pharmaceutical compositions comprise at least one isolated miR gene product and a pharmaceutically-acceptable carrier. In a particular embodiment, the at least one miR gene product corresponds to a miR gene product that has a decreased level of expression in CLL cells relative to suitable control cells. In certain embodiments the isolated miR gene product is selected from the group consisting of miR-29 or miR- 181 and combinations thereof.

[00112] In other embodiments, the pharmaceutical compositions of the invention comprise.at least one miR expression inhibition compound. In a particular embodiment, the at least one miR gene expression inhibition compound is specific for a miR gene whose expression is greater in CLL cells than control cells. In certain embodiments, the miR gene expression inhibition compound is specific for one or more miR gene products selected from the group consisting of consisting of miR-29 or miR-181 and combinations thereof.

[00113] Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free. As used herein, "pharmaceutical formulations" include formulations for human and veterinary use. Methods for preparing pharmaceutical compositions of the invention are within the skill in the art, for example as described in Remington's Pharmaceutical Science, 17th ed., Mack Publishing Company, Easton, Pa. (1985), the entire disclosure of which is incorporated herein by reference.

[00114] The present pharmaceutical formulations comprise at least one miR gene product or miR gene expression inhibition compound (or at least one nucleic acid comprising sequences encoding them) (e.g., 0.1 to 90% by weight), or a physiologically acceptable salt thereof, mixed with a pharmaceutically-acceptable carrier. The pharmaceutical formulations of the invention can also comprise at least one miR gene product or miR gene expression inhibition compound (or at least one nucleic acid comprising sequences encoding them) which are encapsulated by liposomes and a pharmaceutically-acceptable carrier.

[00115] Especially suitable pharmaceutically-acceptable carriers are water, buffered water, normal saline, 0.4% saline, 0.3% glycine, hyaluronic acid and the like.

[00116] In a particular embodiment, the pharmaceutical compositions of the invention comprise at least one miR gene product or miR gene expression inhibition compound (or at least one nucleic acid comprising sequences encoding them) which is resistant to degradation by nucleases. One skilled in the art can readily synthesize nucleic acids which are nuclease resistant, for example by incorporating one or more ribonucleotides that are modified at the 2'-position into the miR gene products.

Suitable 2'-modified ribonucleotides include those modified at the 2'-position with fluoro, amino, alkyl, alkoxy, and O-allyl.

[00117] Pharmaceutical compositions of the invention can also comprise conventional pharmaceutical excipients and/or additives. Suitable pharmaceutical excipients include stabilizers, antioxidants, osmolality adjusting agents, buffers, and pH
adjusting agents. Suitable additives include, e.g., physiologically biocompatible buffers (e.g., tromethamine hydrochloride), additions of chelants (such as, for example, DTPA
or DTPA-bisamide) or calcium chelate complexes (such as, for example, calcium DTPA, CaNaDTPA-bisamide), or, optionally, additions of calcium or sodium salts (for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate).
Pharmaceutical compositions of the invention can be packaged for use in liquid form, or can be lyophilized.

[00118] For solid pharmaceutical compositions of the invention, conventional nontoxic solid pharmaceutically-acceptable carriers can be used; for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.

[00119] For example, a solid pharmaceutical composition for oral administration can comprise any of the carriers and excipients listed above and 10-95%, preferably 25%-75%, of the at least one miR gene product or miR gene expression inhibition compound (or at least one nucleic acid comprising sequences encoding them). A
pharmaceutical composition for aerosol (inhalational) administration can comprise 0.01-20% by weight, preferably 1%-10% by weight, of the at least one miR gene product or miR gene expression inhibition compound (or at least one nucleic acid comprising sequences encoding them) encapsulated in a liposome as described above, and a propellant. A carrier can also be included as desired; e.g., lecithin for intranasal delivery.

[00120] The invention also encompasses methods of identifying an anti-CLL
agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product in the cell. In one embodiment, the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in CLL cells. An increase in the level of the miR gene product in the cell, relative to a suitable control cell, is indicative of the test agent being an anti-CLL agent. In a particular embodiment, at least one miR gene product associated with decreased expression levels in CLL cells is selected from the group consisting of miR-29 or miR- 181 and combinations thereof.

[00121] In other embodiments the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in CLL cells. A decrease in the level of the miR gene product in the cell, relative to a suitable control cell, is indicative of the test agent being an anti-CLL
agent. In a particular embodiment, at least one miR gene product associated with increased expression levels in CLL cells is selected from the group consisting of miR-29 or miR- 181 and combinations thereof.

[00122] Suitable agents include, but are not limited to drugs (e.g., small molecules, peptides), and biological macromolecules (e.g., proteins, nucleic acids).
The agent can be produced recombinantly, synthetically, or it may be isolated (i.e., purified) from a natural source. Various methods for providing such agents to a cell (e.g., transfection) are well known in the art, and several of such methods are described hereinabove. Methods for detecting the expression of at least one miR gene product (e.g., Northern blotting, in situ hybridization, RT-PCR, expression profiling) are also well known in the art.

[00123] The invention will now be illustrated by the following non-limiting examples.

[00124] EXAMPLES

[00125] CLL Samples and microRNA microchip experiments.

[00126] Eighty CLL samples were obtained afte"r informed consent from patients diagnosed with CLL at the CLL Research Consortium institutions. Briefly, blood was obtained from CLL patients, lymphocytes were isolated through FicolUHypaque gradient centrifugation (Amersham, Piscataway, NJ) and processed for RNA
extraction using the standard Trizol method. Protein extraction was carried out as described previously.10 MicroRNA-microchip experiments were performed as previously described.9 Each microRNA microchip contained duplicates probes, corresponding to 326 human and 249 mouse microRNA genes. Statistical analysis was carried out as previously described." To identify statistically significant differentially expressed microRNA, class prediction analyses were performed using BRB ArrayTools.

[00127] DNA-constructs, transfection, Western blotting and luciferase assay.

[00128] Full length TCLI cDNA including 5' and 3' UTRs cDNA was cloned into a pUSEamp vector (Upstate Biotechnology, Chicago, IL) (used in Fig. le).
MiR-29b and miR-181 b RNA duplexes were purchased from Ambion (Austin, TX).
Transfections were carried out as previously described.1Z Firefly and renilla luciferase activities were assayed with the dual luciferase assay system (Promega) and firefly luciferase activity was normalized to renilla luciferase activity. Cell lysate preparations and Western blot analysis were carried out using anti-TCLI monoclonal antibody (clone 27D6) as described previously 4 [00129] Results and discussion.

[00130] High expression of Tcll correlates with aggressive B-CLL
phenotype.

[00131] To evaluate TCLI and microRNA expression in B-CLL samples, three groups of B-CLL were chosen: 23 samples of indolent B-CLL, 25 samples of aggressive B-CLL and 32 samples of aggressive B-CLL showing I lq deletion.
Detailed descriptions of the samples are shown in Figs. 4a-4d.

[00132] MicroRNA microchip experiments revealed that three groups of CLL
show significant characteristic differences in microRNA expression pattern (see Fig. 3 -Table 1 and Fig.5 - Table 2).

[00133] To determine TCLI protein expression in three groups of CLL, Western blot analysis using 27D6 TCL1 monoclonal antibody was carried out. Results of these experiments are shown on Figs. 1 a-b.

[00134] TCLI expression was assessed as low, medium, high and very high. Our experiments revealed low levels in 15 of 23 (65%) indolent B-CLLs, in 11 of 25 (44%) aggressive B-CLLs and in 1 of 32 (3%) aggressive B-CLLs with 11 q deletions;
whereas high and very high TCLI expression was observed in 1 of 23 (4%) indolent B-CLLs, in 14 of 25 (56%) aggressive B-CLLs and in 24 of 32 (75%) aggressive B-CLLs with l lq deletions (Fig. lb).

[00135] It is believed by the inventor herein that TCL1 overexpression correlates with aggressive B-CLL phenotype (p<10"6) and l lq deletions (p<10-4 ). The results are consistent with the recently published study demonstrating that high TCL1 expression in human CLL correlates with unmutated VH status and ZAP70 positivity.5 [00136] MiR-29 and miR-181 target Tcll expression.

[00137] To determine which miRNA(s) target TCLI, RNAhybrid software offered by Bielefeld University Bioinformatics Server and miRBase database13 was used. Among miR-candidates targeting TCL1, it was found that miR-29b and miR-181b (Fig. 1 c, several other sites with lower homology not shown) are also down-regulated in aggressive B-CLLs with 11 q deletions (Fig. 3 - Table 1).

[00138] The expression of these miRs was confirmed by real time RT-PCR in representative set of samples (Figs. 4a-4d).

[00139] Furthermore, it was previously shown that expression of members of miR-29 family could discriminate between CLL samples with good and bad prognosis.9 It was then determined whether these miRs indeed target TCLI expression using the TCL1 3' UTR inserted downstream downstream of luciferase ORF, as previously described.1z HEK293 cells were co-transfected with the miR-29b or scramble negative control, as indicated, and pGL3 construct containing a part of TCLI cDNA
including a region homologous to miR-29 (Tcll) or pGL3 vector alone as indicated.

[00140] For miR-181 assays full length TCLI cDNA was inserted into pGL3 vector in sense (Tc11FL) or anti sense (Tc11FLAS) orientation. Fig. ld shows that TCLI mRNA expression is inhibited by miR-29 and miR-181. To confirm these findings full-length TCL1 cDNA including 5' and 3' UTRs were cloned into CMV
mammalian expression vector and investigated whether miR-29b and miR-181b affect TCLI protein expression levels. We co-transfected this construct with miR-29b, miR-181b and Pre-miR negative control (scramble) into 293 cells as indicated on Fig. 1 e.

[00141] These experiments revealed that co-expression of TCLI with miR-29 and miR-181 significantly decreased TCLI expression (Fig. 1 e, lane 2 versus lanes 1 and 3).

[00142] Thus, it is shown herein that miR-29b and miR-181 b target TCLI
expression on mRNA and protein levels. Interestingly, there was an inverse correlation between miR-29b and miR-181b expression and TCLI protein expression in B-CLL
samples (Fig. if): all samples showing high miR-29b and miR-181b expression also show low or medium TCLI expression; all samples showing very high TCLI
expression show mostly low expression of miR-29b and miR-181b. These results show that TCL1 expression in CLL is, at least in part, regulated by miR-29 and miR-181.

[00143] It is demonstrated herein that TCLI expression is regulated by miR-29 and miR-181 and this regulation is relevant to three groups of B-CLL studied.
Although a reverse correlation between TCLI protein expression and these two miRs was observed, significant proportion of B-CLL samples show low TCL1 expression and low expression of miR-29 and miR-181 (Fig. 10. This suggests that in these samples TCLI
expression is down-regulated transcriptionally or by other miRNAs. The fact that neither miR-29 nor miR-181 is located at 1 lq suggests that that region may contain an important regulator of the expression of these two miRs.

[00144] Interestingly, miR-181 is differentially expressed in B-cells and TCLI
is mostly B-cell specific gene.14 While not wishing to be bound by theory, the inventor herein believes that there is an inverse correlation between TCLI and miR-181 expression at different stages of B-cell maturation. Since miR-29 and miR-181.
are natural TCLI inhibitors, these miRs can be useful candidates for therapeutic agents in B-CLL overexpressing TCLI.

[00145] In accordance with the provisions of the patent statutes, the principle and mode of operation of this invention have been explained and illustrated in its preferred embodiment. However, it must be understood that this invention may be practiced otherwise than as specifically explained and illustrated without departing from its spirit or scope.

[00146] References [00147] The references discussed above and the following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

[00148] 1. Sgambati M, Linet M, Devesa S. Chronic Lymphocytic Leukemia, Epidemiological, Familial, and Genetic Aspects. Chronic Lymphocytic Leukemias, Second Edition, Revised and Expanded, Bruce Cheson, Ed Marcel Dekker, Inc. New York. 200; 33-62.

[00149] 2. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl. Acad. Sci. USA 1994; 91:12530-12534.

[00150] 3. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci.
USA.
2002; 99:6955-6960.

[00151] 4. Pekarsky Y, Koval A, Hallas C, et al. Tcl 1 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl. Acad. Sci. USA
2000;
97:3028-3033.

[00152] 5. Herling M, Patel KA, Khalili J, et al. TCLI shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006; 20:280-285.

[00153] 6. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 2000; 343:1910-1916.

[00154] 7. Ambros V. The functions of animal microRNAs. Nature. 2004;
431:350-355.

[00155] 8. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Nati. Acad.
Sci.
USA. 2004; 101:11755-11760.

[00156] 9. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N.
Engl. J.
Med. 2005; 353:1793-1801.

[00157] 10. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates Tall oncoprotein and inhibits its repressor activity.
Cancer Res. 2005; 65 :4515-4519.

[00158] 11. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad.
Sci.
USA. 2006; 103:2257-2261.

[00159] 12. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA. 2005; 102:13944-13949.

[00160] 13. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34:D140-144.
[001611 14. Ramkissoon SH, Mainwaring LA, Ogasawara Y, et al.
Hematopoietic-specific microRNA expression in human cells. Leuk Res. 2005.

Claims

1. A method of diagnosing whether a subject has, or is at risk for developing, chronic lymphocytic leukemia (B-CLL), comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, B-CLL.

2. The method of Claim 1, wherein the at least one miR gene product is miR-29 or miR-181.

3. The method of Claim 1, wherein the at least one miR gene product is miR-29b.

4. The method of Claim 1, wherein the at least one miR gene product is miR-181b.

5. The method of Claim 1, wherein the level of the at least one miR gene product is measured using Northern blot analysis.

6. The method of Claim 1, wherein the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR
gene product in the control sample.

7. The method of Claim 1, wherein the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR
gene product in the control sample.

8. A method of diagnosing a B-CLL associated with one or more prognostic markers in a subject, comprising measuring the level of at least one miR
gene product in a B-CLL sample from said subject, wherein an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject having a B-CLL associated with the one or more prognostic markers.

9. A method of diagnosing whether a subject has, or is at risk for developing, B-CLL, comprising:
(1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample; and, (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample, wherein an alteration in the signal of at least one miRNA is indicative of the subject either having, or being at risk for developing, B-CLL.

10. The method of Claim 9 wherein the signal of at least one miRNA, relative to the signal generated from the control sample, is down-regulated.

11. The method of Claim 9 wherein the signal of at least one miRNA, relative to the signal generated from the control sample, is up-regulated.

12. The method of Claim 9 wherein the microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR-29 or miR-181 and combinations thereof.

13. A method of diagnosing whether a subject has, or is at risk for developing, a B-CLL associated with one or more adverse prognostic markers in a subject, comprising:
(1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
(2) hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for said test sample; and, (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample, wherein an alteration in the signal is indicative of the subject either having, or being at risk for developing, the cancer.

14. The method of Claim 13, wherein the microarray comprises at least one miRNA-specific probe oligonucleotide for a miRNA selected from the group consisting of miR-29 or miR- 181 and combinations thereof.

15. A method of treating B-CLL in a subject who has a B-CLL in which at least one miR gene product is down-regulated or up-regulated in the cancer cells of the subject relative to control cells, comprising:
(1) when the at least one miR gene product is down-regulated in the cancer cells, administering to the subject an effective amount of at least one isolated miR gene product, such that proliferation of cancer cells in the subject is inhibited;
or (2) when the at least one miR gene product is up-regulated in the cancer cells, administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, such that proliferation of cancer cells in the subject is inhibited.

16. The method of Claim 15, wherein the at least one isolated miR gene product in step (1) is selected miR-29, miR-181 and combinations thereof.

17. The method of Claim 15, wherein the at least one miR gene product in step (2) is selected from the group consisting of miR-291, miR-181 and combinations thereof.

18. A method of treating B-CLL in a subject, comprising:
(1) determining the amount of at least one miR gene product in B-CLL
cells, relative to control cells; and (2) altering the amount of miR gene product expressed in the B-CLL cells by:
i) administering to the subject an effective amount of at least one isolated miR gene product, if the amount of the miR gene product expressed in the cancer cells is less than the amount of the miR gene product expressed in control cells; or ii) administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, if the amount of the miR gene product expressed in the cancer cells is greater than the amount of the miR gene product expressed in control cells, such that proliferation of cancer cells in the subject is inhibited.

19. The method of Claim 18, wherein the at least one isolated miR gene product in step (i) is selected from the group consisting of miR-29, miR-181, and combinations thereof.

20. The method of Claim 18, wherein the at least one miR gene product in step (ii) is selected from the group consisting of miR-29, miR-181, and combinations thereof.

21. A pharmaceutical composition for treating B-CLL, comprising at least one isolated miR gene product and a pharmaceutically-acceptable carrier.

22. The pharmaceutical composition of Claim 21, wherein the at least one isolated miR gene product corresponds to a miR gene product that is down-regulated in B-CLL cells relative to suitable control cells.

23. The pharmaceutical composition of Claim 22, wherein the isolated miR
gene product is selected from the group consisting of miR-29, miR-181 and combinations thereof.

24. A pharmaceutical composition for treating B-CLL, comprising at least one miR expression inhibitor compound and a pharmaceutically-acceptable carrier.

25. The pharmaceutical composition of Claim 24, wherein the at least one miR expression inhibitor compound is specific for a miR gene product that is up-regulated in B-CLL cells relative to suitable control cells.

26. The pharmaceutical composition of Claim 25, wherein the at least one miR expression inhibitor compound is specific for a miR gene product selected from the group consisting of miR-29, miR-181 and combinations thereof.

27. A method of identifying an anti-B-CLL agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in B-CLL cells, wherein an increase in the level of the miR gene product in the cell, relative to a suitable control cell, is indicative of the test agent being an anti-B-CLL agent.

28. The method of Claim 27, wherein the miR gene product is selected from the group consisting of miR-29, miR-181 and combinations thereof.

29. A method of identifying an anti-B-CLL agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in B-CLL cells, wherein an decrease in the level of the miR gene product in the cell, relative to a suitable control cell, is indicative of the test agent being an anti-B-CLL agent.

30. The method of Claim 29, wherein the miR gene product is selected from the group consisting of miR-29, miR- 181 and combinations thereof.